15 recruiting. 15 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Recruiting 15 |
| Phase 1 | 7 | Recruiting 7 |
| Phase 3 | 1 | Recruiting 1 |
Follow Hearing Loss: new trials by email Literature Review of Hearing Loss trials Research Report on Hearing Loss
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPI-1005 in Adults Receiving Cochlear Implant Ebselen, Placebo - Hearing Loss, Cochlear Trauma | Phase 2 | Recruiting | Sound Pharmaceuticals, Incorporated | 40 | 2026-12-01 | 2026-06-26 |
| Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss SKY-GJB2 - GJB2-mediated Hearing Loss, GJB2 Gene Mutation | Phase 1 / Phase 2 | Recruiting | Skylark Bio Inc. | 10 | 2026-05-28 | 2026-08-27 |
| Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS) Pedmark® STS - Solid Tumor Malignancies, Testicular Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 25 | 2026-05-18 | 2026-06-18 |
| First Clinical Study to Evaluate Safety, Tolerability & PK of DX243 in Healthy Volunteers and Patients With Hearing Loss DX243, Placebo - Age-related Hearing Loss | Phase 2 | Recruiting | Dendrogenix | 24 | 2026-05-13 | 2026-06-10 |
| A Prospective, Open-label, Pivotal Study to Assess Spectacle Hearing Aid Safety and Efficacy Spectacle Hearing Aid - Hearing Loss Mixed | Phase 2 / Phase 3 | Recruiting | Nuance Hearing | 89 | 2025-07-27 | 2025-12-15 |
| Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin ORC-13661, Placebo - Ototoxicity, Drug-Induced | Phase 2 | Recruiting | Kevin Winthrop | 105 | 2025-06-02 | 2026-10-01 |
| A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound Clemastine Fumarate Combined With Engineered Sound, Clemastine Fumarate Combined With Pink Noise, Placebo Drug With Engineered Sound - Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 344 | 2025-03-31 | 2026-04-30 |
| A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO) OpCT-001 - Primary Photoreceptor Disease, Retinitis Pigmentosa (RP) | Phase 1 / Phase 2 | Recruiting | BlueRock Therapeutics | 54 | 2025-03-10 | 2026-10-15 |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 27 | 2025-01-17 | 2026-11-04 |
| Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial Acetyl cysteine, Normal Saline - Cisplatin-induced Ototoxicity, Sensorineural Hearing Loss | Phase 2 | Recruiting | Siriraj Hospital | 40 | 2024-12-23 | 2026-01-23 |
| Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss Hydroxychloroquine, Steroid - Sudden Hearing Loss | Phase 2 | Recruiting | Chang Gung Memorial Hospital | 80 | 2024-09-10 | 2026-10-22 |
| Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer Placebo, Atorvastatin - Hearing Loss, Head and Neck Cancer | Phase 2 | Recruiting | National Institute on Deafness and Other Communication Disorders (NIDCD) | 224 | 2024-07-10 | 2026-09-02 |
| Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa AAVB-081 - Usher Syndrome, Type 1B | Phase 1 / Phase 2 | Recruiting | AAVantgarde Bio Srl | 15 | 2024-07-02 | 2025-05-02 |
| A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations DB-OTO - Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 36 | 2023-06-27 | 2026-08-05 |
| Efficacy of Sodium Thiosulfate and Mannitol in Reducing Ototoxicity in Adult Patients Receiving Cisplatin Chemotherapy Sodium Thiosulfate + Mannitol - Ototoxic Hearing Loss | Phase 2 | Recruiting | Sunnybrook Health Sciences Centre | 92 | 2023-02-15 | 2023-04-14 |
Hearing Loss, Sensorineural (5) · Deafness (2) · Head and Neck Neoplasms (2) · Hearing Disorders (2) · Ototoxicity (2) · Presbycusis (2) · Retinitis Pigmentosa (2) · Usher Syndromes (2) · Auditory Diseases, Central (1) · Auditory neuropathy (1) · Carcinoma, Squamous Cell (1) · Cone-Rod Dystrophies (1) · Deafness, Autosomal Recessive 1A (1) · Deafness, Autosomal Recessive 9 (1)
Nervous System Diseases (15) · Neurologic Manifestations (15) · Otorhinolaryngologic Diseases (15) · Pathological Conditions, Signs and Symptoms (15) · Sensation Disorders (15) · Signs and Symptoms (15) · Ear Diseases (14) · Hearing Disorders (13) · Hearing Loss, Sensorineural (3) · Neoplasms by Site (3) · Abnormalities, Multiple (2) · Blindness (2) · Chemically-Induced Disorders (2) · Congenital Abnormalities (2)
Acetylcysteine (1) · Atorvastatin (1) · Clemastine (1) · Hydroxychloroquine (1) · Mannitol (1) · ORC-13661 (1) · OTOF protein, human (1) · Placebo Effect (1) · Saline Solution (1) · Steroids (1) · ebselen (1) · sodium thiosulfate (1)
AAVantgarde Bio Srl (1) · BlueRock Therapeutics (1) · Chang Gung Memorial Hospital (1) · Dendrogenix (1) · Eli Lilly and Company (1) · Kevin Winthrop (1) · National Institute on Deafness and Other Communication Disorders (NIDCD) (1) · Nuance Hearing (1) · Regeneron Pharmaceuticals (1) · Siriraj Hospital (1) · Skylark Bio Inc. (1) · Sound Pharmaceuticals, Incorporated (1) · Sunnybrook Health Sciences Centre (1) · University of Arizona (1) · University of Colorado, Denver (1)
United States (9) · United Kingdom (2) · Belgium (1) · Canada (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Spain (1) · Taiwan (1) · Thailand (1)
Aaron Tward, MD (1) · Achim Klug, PhD (1) · Alejandro Recio-Boiles, MD (1) · Chao-Hui Yang (1) · Edwin Rubel, PhD (1) · Kanthong Thongyai, Master (1) · Kevin L Winthrop, MD, MPH (1) · Lisa Davis, PharmD (1) · Lisa L Cunningham, Ph.D. (1) · Samuel A Budoff, PhD, MS (1)
2023 (1), U01DC020175 (1)